氧化chloroquine 心脏毒性和沙尔科梅里克高性心肌病变
Tauben Averbuch1, Jeffrey Shaw2, Kristin Lyons2
1Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada.
JACC. Case reports
|June 13, 2025
概括
氧化对心脏有毒性可以模仿或恶化多变性心肌病. 像心脏MRI和活检这样的诊断工具对于识别风险患者心脏病的未被认可的原因至关重要.
科学领域:
- 心脏病学 心脏病学
- 毒理学 毒理学 毒理学
- 遗传学 是一个遗传学.
背景情况:
- 氧化对心脏有毒性是一种罕见但严重的疾病.
- 它可以表现为扩张或限制性心肌病.
- 这种毒性在患有先前心脏病的患者中可能特别具有挑战性.
研究的目的:
- 突出氧化chloroquine心脏毒性作为心肌病的未被认可的原因.
- 强调高级成像和活检在叠加性心脏毒性的诊断实用性.
- 强调在恶化的心脏病中考虑药物毒性的重要性.
主要方法:
- 一个50岁的男性患有缩性心肌病变和心室性心力衰竭的病例介绍.
- 使用心脏磁共振成像 (CMR) 进行详细的心脏评估.
- 进行了内肌心活检 (EMB) 进行组织学分析.
- 进行基因检测以确定潜在的心肌病.
主要成果:
- CMR显示了双心室缩,静脉缩功能障碍和扩散非缺血性纤维化.
- 电磁波揭示了与缩性心肌病症和氧化心脏毒性 (真空肌细胞,骨髓体) 一致的特征.
- 基因检测证实了一种致病性MYBPC3变体,诊断出了sarcomeric高性心肌病变.
结论:
- 氧化对心脏有毒性是一种未被认可的病因,特别是当叠加于现有的心肌病症时.
- 在复杂的病例中,CMR,EMB和基因检测对于诊断的明确性至关重要.
- 及时诊断有助于适当的管理和对遗传变异的级联查.
相关概念视频
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K


